Skip to main content
NCBI home page
Biophysical Journal logoLink to Biophysical Journal
. 2000 Feb;78(2):590–599. doi: 10.1016/S0006-3495(00)76619-7

Stereochemical requirements for receptor recognition of the mu-opioid peptide endomorphin-1.

M G Paterlini 1, F Avitabile 1, B G Ostrowski 1, D M Ferguson 1, P S Portoghese 1
PMCID: PMC1300664  PMID: 10653774

Abstract

A series of diastereoisomers of endomorphin-1 (EM1, Tyr(1)-Pro(2)-Trp(3)-Phe(4)-NH(2)) have been synthesized and their potency measured using the guinea pig ileum assay. [D-Phe(4)]EM1 possessed 1/10 the potency of EM1, while potencies of [D-Tyr(1)]EM1 and [D-Trp(3)]EM1 were 50- and 100-fold lower, respectively. Drastic loss of activity occurred in the [D-Pro(2)]EM1 peptide. The structural determinants for the inactivity and reduced potency of the diastereoisomers were investigated using NMR spectroscopy and conformational analysis. Simulations of trans-[D-Pro(2)]EM1 using NOE-derived distance constraints afforded well-defined structures in which Tyr and Trp side chains stack against the proline ring. The inactivity of [D-Pro(2)]EM1 was explained by structural comparison with EM1 (, FEBS Lett. 439:13-20). The two peptides showed an opposite orientation of the Trp(3) residue with respect to Tyr(1), thus suggesting a role of Pro(2) as a stereochemical spacer in orienting Trp(3) and Phe(4) toward regions suitable for mu-receptor interaction. The agonist activity of [D-Tyr(1)]EM1 and [D-Trp(3)]EM1 was attributed to their ability to adopt low-energy conformations that mimic those of EM1. The requirements for mu-receptor activation were examined further by comparing EM1 with the mu-peptide [D-Ala(2), MePhe(4), Gly-ol]-enkephalin (DAMGO). Conformations of DAMGO with a Tyr(1)-MePhe(4) phenyl ring separation of approximately 12 A were found to mimic Tyr(1)-Phe(4) of EM1, thus suggesting overlapping binding modes between these two peptides.

Full Text

The Full Text of this article is available as a PDF (258.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Alt A., Mansour A., Akil H., Medzihradsky F., Traynor J. R., Woods J. H. Stimulation of guanosine-5'-O-(3-[35S]thio)triphosphate binding by endogenous opioids acting at a cloned mu receptor. J Pharmacol Exp Ther. 1998 Jul;286(1):282–288. [PubMed] [Google Scholar]
  2. Amodeo P., Naider F., Picone D., Tancredi T., Temussi P. A. Conformational sampling of bioactive conformers: a low-temperature NMR study of 15N-Leu-enkephalin. J Pept Sci. 1998 Jun;4(4):253–265. doi: 10.1002/(SICI)1099-1387(199806)4:4%3C253::AID-PSC142%3E3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  3. Carpenter K. A., Schiller P. W., Schmidt R., Wilkes B. C. Distinct conformational preferences of three cyclic beta-casomorphin-5 analogs determined using NMR spectroscopy and theoretical analysis. Int J Pept Protein Res. 1996 Jul;48(1):102–111. doi: 10.1111/j.1399-3011.1996.tb01112.x. [DOI] [PubMed] [Google Scholar]
  4. Chang K. J., Lillian A., Hazum E., Cuatrecasas P., Chang J. K. Morphiceptin (NH4-tyr-pro-phe-pro-COHN2): a potent and specific agonist for morphine (mu) receptors. Science. 1981 Apr 3;212(4490):75–77. doi: 10.1126/science.6259732. [DOI] [PubMed] [Google Scholar]
  5. Chang K. J., Wei E. T., Killian A., Chang J. K. Potent morphiceptin analogs: structure activity relationships and morphine-like activities. J Pharmacol Exp Ther. 1983 Nov;227(2):403–408. [PubMed] [Google Scholar]
  6. D'Ursi A., Pegna M., Amodeo P., Molinari H., Verdini A., Zetta L., Temussi P. A. Solution conformation of tuftsin. Biochemistry. 1992 Oct 13;31(40):9581–9586. doi: 10.1021/bi00155a010. [DOI] [PubMed] [Google Scholar]
  7. Delaglio F., Grzesiek S., Vuister G. W., Zhu G., Pfeifer J., Bax A. NMRPipe: a multidimensional spectral processing system based on UNIX pipes. J Biomol NMR. 1995 Nov;6(3):277–293. doi: 10.1007/BF00197809. [DOI] [PubMed] [Google Scholar]
  8. Gong J., Strong J. A., Zhang S., Yue X., DeHaven R. N., Daubert J. D., Cassel J. A., Yu G., Mansson E., Yu L. Endomorphins fully activate a cloned human mu opioid receptor. FEBS Lett. 1998 Nov 13;439(1-2):152–156. doi: 10.1016/s0014-5793(98)01362-3. [DOI] [PubMed] [Google Scholar]
  9. Harrison L. M., Kastin A. J., Zadina J. E. Differential effects of endomorphin-1, endomorphin-2, and Tyr-W-MIF-1 on activation of G-proteins in SH-SY5Y human neuroblastoma membranes. Peptides. 1998;19(4):749–753. doi: 10.1016/s0196-9781(98)00022-9. [DOI] [PubMed] [Google Scholar]
  10. Higashijima T., Kobayashi J., Nagai U., Miyazawa T. Nuclear-magnetic-resonance study on Met-enkephalin and Met-enkephalinamide. Molecular association and conformation. Eur J Biochem. 1979 Jun;97(1):43–57. doi: 10.1111/j.1432-1033.1979.tb13084.x. [DOI] [PubMed] [Google Scholar]
  11. Milon A., Miyazawa T., Higashijima T. Transferred nuclear Overhauser effect analyses of membrane-bound enkephalin analogues by 1H nuclear magnetic resonance: correlation between activities and membrane-bound conformations. Biochemistry. 1990 Jan 9;29(1):65–75. doi: 10.1021/bi00453a009. [DOI] [PubMed] [Google Scholar]
  12. Narita M., Mizoguchi H., Oji G. S., Tseng E. L., Suganuma C., Nagase H., Tseng L. F. Characterization of endomorphin-1 and -2 on [35S]GTPgammaS binding in the mouse spinal cord. Eur J Pharmacol. 1998 Jun 26;351(3):383–387. doi: 10.1016/s0014-2999(98)00395-1. [DOI] [PubMed] [Google Scholar]
  13. Penkler L. J., Van Rooyen P. H., Wessels P. L. Conformational analysis of mu-selective [D-Ala2,MePhe4]enkephalins. Int J Pept Protein Res. 1993 Mar;41(3):261–274. doi: 10.1111/j.1399-3011.1993.tb00334.x. [DOI] [PubMed] [Google Scholar]
  14. Picone D., D'Ursi A., Motta A., Tancredi T., Temussi P. A. Conformational preferences of [Leu5]enkephalin in biomimetic media. Investigation by 1H NMR. Eur J Biochem. 1990 Sep 11;192(2):433–439. doi: 10.1111/j.1432-1033.1990.tb19245.x. [DOI] [PubMed] [Google Scholar]
  15. Podlogar B. L., Paterlini M. G., Ferguson D. M., Leo G. C., Demeter D. A., Brown F. K., Reitz A. B. Conformational analysis of the endogenous mu-opioid agonist endomorphin-1 using NMR spectroscopy and molecular modeling. FEBS Lett. 1998 Nov 13;439(1-2):13–20. doi: 10.1016/s0014-5793(98)01202-2. [DOI] [PubMed] [Google Scholar]
  16. Portoghese P. S., Lipkowski A. W., Takemori A. E. Binaltorphimine and nor-binaltorphimine, potent and selective kappa-opioid receptor antagonists. Life Sci. 1987 Mar 30;40(13):1287–1292. doi: 10.1016/0024-3205(87)90585-6. [DOI] [PubMed] [Google Scholar]
  17. Portoghese P. S., Takemori A. E. TENA, a selective kappa opioid receptor antagonist. Life Sci. 1985 Feb 25;36(8):801–805. doi: 10.1016/0024-3205(85)90202-4. [DOI] [PubMed] [Google Scholar]
  18. RANG H. P. STIMULANT ACTIONS OF VOLATILE ANAESTHETICS ON SMOOTH MUSCLE. Br J Pharmacol Chemother. 1964 Apr;22:356–365. doi: 10.1111/j.1476-5381.1964.tb02040.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Schiller P. W., Nguyen T. M., Weltrowska G., Wilkes B. C., Marsden B. J., Lemieux C., Chung N. N. Differential stereochemical requirements of mu vs. delta opioid receptors for ligand binding and signal transduction: development of a class of potent and highly delta-selective peptide antagonists. Proc Natl Acad Sci U S A. 1992 Dec 15;89(24):11871–11875. doi: 10.1073/pnas.89.24.11871. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Schwartz R. W., Chang A. C., Portoghese P. S., Berzetei-Gurske I. P. A guinea pig ileum preparation devoid of functional kappa receptors: a new in vitro pharmacologic assay for mu-opioid ligands. Life Sci. 1997;60(15):PL235–PL239. doi: 10.1016/s0024-3205(97)00076-3. [DOI] [PubMed] [Google Scholar]
  21. Sim L. J., Liu Q., Childers S. R., Selley D. E. Endomorphin-stimulated [35S]GTPgammaS binding in rat brain: evidence for partial agonist activity at mu-opioid receptors. J Neurochem. 1998 Apr;70(4):1567–1576. doi: 10.1046/j.1471-4159.1998.70041567.x. [DOI] [PubMed] [Google Scholar]
  22. Williamson M. P., Havel T. F., Wüthrich K. Solution conformation of proteinase inhibitor IIA from bull seminal plasma by 1H nuclear magnetic resonance and distance geometry. J Mol Biol. 1985 Mar 20;182(2):295–315. doi: 10.1016/0022-2836(85)90347-x. [DOI] [PubMed] [Google Scholar]
  23. Zadina J. E., Hackler L., Ge L. J., Kastin A. J. A potent and selective endogenous agonist for the mu-opiate receptor. Nature. 1997 Apr 3;386(6624):499–502. doi: 10.1038/386499a0. [DOI] [PubMed] [Google Scholar]

Articles from Biophysical Journal are provided here courtesy of The Biophysical Society

RESOURCES